Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.

Author: BregaNicoletta, DimaLaura, DrilonAlexander, KummarShivaani, LassenUlrik N, LeyvrazSerge, LinJessica J, LiuYongmei, MorenoVictor, NorenbergRicarda, PatelJyoti D, RosenLee, ShenLin, SolomonBenjamin, TanDaniel S W

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancers.
Paper Details　
Original Abstract of the Article :
Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion-positive cancers, regardless of the tumor type. The aim of this study was to assess the efficacy and safety of larotrectinib in patients with TRK fusion-pos...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830513/

データ提供：米国国立医学図書館（NLM）

The Efficacy of Larotrectinib in Treating TRK Fusion-Positive Lung Cancers

Larotrectinib is a novel targeted therapy that shows promise in treating various cancers with [tropomyosin receptor kinase (TRK)] fusions. This study assesses the efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancers.

Larotrectinib's Effectiveness in Lung Cancer

The study demonstrates the efficacy of larotrectinib in treating TRK fusion-positive lung cancers, highlighting its potential as a valuable treatment option for this specific type of lung cancer. Larotrectinib's ability to target TRK fusions offers a targeted approach to cancer treatment.

Improving Treatment Outcomes for Lung Cancer Patients

This research provides valuable insights into the potential of larotrectinib for treating TRK fusion-positive lung cancers, offering hope for better outcomes for patients with this challenging diagnosis. The study encourages further research to expand the use of targeted therapies in treating lung cancer.

Dr.Camel's Conclusion

This study, like a refreshing spring in the arid landscape of lung cancer treatment, reveals the potential of larotrectinib in treating TRK fusion-positive lung cancers. The research offers hope for personalized treatment approaches, paving the way for a more targeted and effective approach to combatting this devastating disease.

Date :
  1. Date Completed 2022-03-24
  2. Date Revised 2023-04-03
Further Info :

Pubmed ID

35085007

DOI: Digital Object Identifier

PMC8830513

Related Literature

Article Analysis
・Effects of larotrectinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.